Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Vote in favor of your Favored Travel Movement - 2Illegal entries into Germany halve over two years, border police say
- 36 Fun Urban areas For Seniors To Travel
- 4Productive CRM Programming for Client Relationship The executives
- 5'The Boys' Season 5 premiere: How to watch for less, what to know about the final series and more
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
- Violence 'never part' of break-in plan, court told
- Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- 'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- 10 Demonstrated Systems to Develop Your Internet based Business
- The Main 15 Applications for Efficiency and Association
- This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
